lymphocytes

[Proceedings of the National Academy of Sciences of the United States of America] To advance the development of natural killer (NK)-based therapies, scientists developed a functional screen to rapidly identify antibodies that can activate NK cells. They displayed antibodies on a mammalian target cell line and probed their ability to stimulate NK cell-mediated cytotoxicity.

[Leukemia] Loss of both SHMT1 and SHMT2 was necessary for impaired growth and cell cycle arrest, with suppression of both SHMT1 and SHMT2 inhibiting leukemia progression in vivo.

[Acta Pharmacologica Sinica] Bisthianostat dose dependently induced acetylation of tubulin and H3 and increased PARP cleavage and apoptosis in RPMI-8226 cells. In RPMI-8226 and MM.1S cell xenograft mouse models, oral administration of bisthianostat for 18 days dose dependently inhibited tumor growth.

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master iPSC line.

[Proceedings of the National Academy of Sciences of the United States of America] Using ex vivo human primary T cells, researchers found that PIP4K activity was required for Treg cell signaling and immunosuppressive activity. Genetic and pharmacological inhibition of PIP4K in Tregs reduced signaling through the PI3K, mTORC1/S6, and MAPK pathways, impaired cell proliferation, and increasedactivation-induced cell death while sparing Tconv.

[Nature Immunology] Scientists confirmed pervasive phenotypic, functional and transcriptional differences between memory and exhausted antigen-specific CD8+ T cells in human hepatitis C virus (HCV) infection before and after treatment.